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The purification of a 68-kDa hyaluronic acid-binding
protein (HA-binding protein), a homodimer of 34 kDa
that binds specifically to hyaluronic acid, has been re-
ported earlier by us (Gupta, S., Batchu, R. B., and Datta,
K. (1991) Eur. J. Cell Biol. 56, 58–67). Here, we report the
isolation of a partial cDNA clone from a l gt11 cDNA
expression library of human skin fibroblast by immuno-
screening with HA-binding protein antiserum. The in-
ternal polypeptide sequence (83 residues) of the purified
hyaluronic acid-binding protein is identical to the pre-
dicted protein sequence derived from hyaluronic acid-
binding protein cDNA, suggesting the authenticity of
the clone. Interestingly, this hyaluronic acid-binding
protein cDNA sequence has complete homology with the
cDNA sequence of a protein P-32, co-purified with the
human pre-mRNA splicing factor SF2 (Krainer, A. R.,
Mayeda, A., Kozak, D., and Binns, G. (1991) Cell 66, 383–
394). Furthermore, the data on the N-terminal sequence
of hyaluronic acid-binding protein and the predicted
polypeptide of P-32 revealed the identical coding se-
quence of 209 amino acids for both the proteins. As the
identity and functional characterization of P-32 have
not yet been reported, P-32 cDNAwas expressed in Esch-
erichia coli, and the recombinant P-32 protein was pu-
rified by hyaluronic acid-Sepharose affinity chromatog-
raphy. The recombinant P-32 protein showed immuno-
cross-reactivity with the polyclonal antibodies raised
against HA-binding protein. The predicted amino acid
sequence of the protein fulfilled the minimal criteria for
binding to hyaluronic acid, i.e. two basic amino acids
flanking a seven-amino acid stretch, as reported for
other hyaluronic acid-binding proteins. Furthermore,
the hyaluronic acid affinity of the recombinant P-32
protein was confirmed by biotinylated hyaluronic acid
binding assay. The binding of recombinant P-32 protein
to biotinylated hyaluronic acid can be competed only
with excess unlabeled hyaluronic acid, confirming its
specificity toward hyaluronic acid. All these results sug-
gest that both P-32, co-purified with the human
pre-mRNA splicing factor SF2, and 34-kDa hyaluronic
acid-binding protein reported by us are the same pro-
tein and that it is a new member of the hyaluronic acid-
binding protein family, the “hyaladherins.”
Hyaluronic acid (HA),1 a viscoelastic, high molecular weight,
nonsulfated glycosaminoglycan, is ubiquitously present in both
the extracellular space and the nucleus of higher animals (1–5).
The biological functions of HA include not only physiological
roles such as maintenance of matrix structure and water bal-
ance (6, 7) but also cellular functions like proliferation (6, 8),
tissue recognition (7), and locomotion (9). The cell type-specific
functions of HA are mediated through its interaction with
HA-binding proteins (7).
A number of extracellular as well as cell-surface HA-binding
proteins are known to mediate the multifaceted regulations of
HA-induced cellular functions (10–19). Due to the presence of
defined HA-binding motif, these proteins are expected to be-
long to one family, recently, referred to as “hyaladherins” (20).
Few of them are molecularly characterized, and their sequence
data confirm their distinction.
The purification of 68-kDa homodimer (34-kDa subunit) HA-
binding protein from rat kidney tissue and its specificity to-
ward hyaluronic acid were confirmed earlier from our labora-
tory (21). The differential expression of this glycoprotein on the
cell surface of AK-5, a transplantable histiocytic tumor cell line,
and its role in cell adhesion were also demonstrated (22). Ran-
ganathan et al. (23) observed the in vivo phosphorylation of this
protein in motile spermatozoa and established its role in sperm
maturation, motility, and fertilization. To understand the reg-
ulation of expression of this protein and its precise role in
cellular functions, we have cloned the gene encoding this 34-
kDa HA-binding protein. A l gt11 human skin fibroblast cDNA
expression library was screened with antibodies raised against
this HA-binding protein. Partial cDNA sequence analysis and
the deduced amino acid sequence match with the amino acid
sequence of purified HA-binding protein. Interestingly, the se-
quence analysis of the HA-binding protein confirms its homol-
ogy with P-32, a protein co-purified with pre-mRNA splicing
factor SF2 from human HeLa cells described by Krainer et al.
(24, 25). The identity and functional characterization of P-32
protein was not known earlier. Here, we report the 34-kDa
HA-binding protein to be the same as P-32 from sequence
analysis and also describe the purification of recombinant P-32
protein by HA-Sepharose column, thus again confirming the
identity of P-32 protein as an HA-binding protein. This result is
also supported by immunological and biochemical studies
showing the specificity of HA affinity of this protein.
EXPERIMENTAL PROCEDURES
Materials—Hyaluronic acid (human umbilical cord, grade 1) was
purchased from Sigma. AH-Sepharose 4B was from Pharmacia Biotech
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Inc. Human skin fibroblast l gt11 cDNA libray was from Clontech, Palo
Alto, CA. CircumVentTM thermal sequencing kit was procured from
New England Biolabs. Enhanced chemiluminescence (ECL) Western
blot kit was from Amersham Corp. All other routine reagents were
purchased from Sigma.
Purification of HA-binding Protein and Development of Polyclonal
Antibodies—HA-binding protein has been purified from rat kidney tis-
sue by using HA-Sepharose affinity chromatography (21). Briefly, HA
from human umbilical cord (grade 1) was coupled to AH-Sepharose 4B
(Pharmacia) according to the manufacturer’s instructions, resulting in
an HA-Sepharose gel. The supernatant after centrifuging the homoge-
nate at 48,000 3 g was fractionated by 70% ammonium sulfate at 4 °C
for 30 min, dialyzed against phosphate-buffered saline and loaded onto
the HA-Sepharose column. Nonspecifically bound proteins were washed
out with 10 volumes of 0.5 M NaCl in 10 mM phosphate buffer, pH 7.2,
and the HA-binding protein was eluted with 0.2 M glycine-HCl, pH 2.2,
at a flow rate of 20 ml/h. Polyclonal antibodies against this purified
HA-binding protein were developed in rabbit. IgG fraction was purified
by protein A-Sepharose CL-4B column and used for immunoscreening a
human skin fibroblast l gt11 cDNA expression library.
Partial Amino Acid Sequence Analysis and Determination of N Ter-
minus of HA-binding Protein—The purified HA-binding protein was
denaturated in 6 M guanidine overnight and precipitated with 10 vol-
umes of ethanol. The precipitate was suspended in 0.2 M ammonium
hydrogen carbonate and cleaved with endoproteinase Asp-N (enzyme:
substrate ratio, 1:50) at 23 °C overnight. The mixture was acidified to
pH 1 with trifluoroacetic acid, and the peptides were separated on a
C-18 reversed phase column (Vydac, 4.6 3 250 mm) using 0.1% triflu-
oroacetic acid (solvent A) and 70% acetonitrile in 0.1% trifluoroacetic
acid (solvent B) with a gradient from 0 to 60% B for 160 min at a flow
rate of 0.25 ml/min. Amino acid sequences were determined with gas-
liquid phase sequencers 470 A and 473 A (Applied Biosystems) as per
the manufacturer’s instructions.
Immunoscreening, Cloning, and Sequencing of Human Skin Fibro-
blast cDNA of HA-binding Protein—A human skin fibroblast l gt11
cDNA library (1.1 3 106 clones; Clontech) was screened with HA-
binding protein polyclonal antibodies (IgG) according to the manufac-
turer’s kit protocol. After three rounds of screening, positive signals
were chosen. l DNA was purified by the plate lysate method (26). The
cDNA insert was polymerase chain reaction (PCR)-amplified using l
gt11 forward and reverse primers and AmpliTaq (Perkin-Elmer) as
described in Perkin-Elmer protocol for DNA amplifications. The reac-
tion was carried out at 94 °C (1 min), 55 °C (1 min), and 70 °C (2 min)
for a total of 30 cycles following a final 10-min elongation step at 72 °C
(27). The PCR product (;0.9 kb) was directly sequenced by Sanger’s
dideoxynucleotide chain termination method (28) using CircumVentTM
thermal cycle sequencing kit (New England Biolabs) and l gt11 forward
and reverse primers. A sequence of 400 bases was obtained, and this
sequence completely matched with the P-32 cDNA sequence (24) upon
alignment. The PCR product was subcloned in EcoRV opened pBlue-
script KS(1) (Stratagene, La Jolla, CA) as described by Sambrook et al.
(26). The remaining part of cDNA insert in the minipreparation of
pBluescript KS(1) was sequenced using two internal primers 59-TTG
GAC AAG AAG ACG AGG CTG-39 and 59-AGT TTC ATG GCA GGC
TTT GGC-39 (National Biosciences, Plymouth, MN), which were de-
signed based on the published cDNA sequence of P-32 (24).
Purification of Recombinant P-32 Protein by HA-Sepharose Chroma-
tography—The expression clone representing the mature P-32 protein
(209 amino acids) was a generous gift from Dr. Adrian R. Krainer (Cold
Spring Harbor Laboratory, NY) and expressed in BL 21(3E) as de-
scribed (24). Bacterial cultures were induced for 3 h with 0.4 mM IPTG
when the A600 reached 1. The cells were harvested, washed, and sus-
pended in 0.1 M NaCl, 10 mM Tris-Cl (pH 8.0) and lysed with lysozyme
for 30 min at room temperature. Complete lysis was achieved by soni-
cation on ice in 10-s bursts at 30-s intervals. The lysate was centrifuged
at 12,000 rpm for 30 min, and clear supernatant containing soluble
recombinant P-32 was loaded onto an HA-Sepharose affinity column.
Recombinant P-32 was purified using the same protocol used for the
purification of tissue HA-binding protein as described before. Polyclonal
antibodies against purified recombinant P-32 were raised in rabbit.
SDS-PAGE and Two-dimensional Gel Electrophoresis—SDS-PAGE
of purified HA-binding protein, recombinant P-32, and bacterial lysates
were performed as described by Laemmli (29). Proteins were stained
with 0.1% Coomassie Brilliant Blue in 25% methanol and 10% acetic
acid. Two-dimensional gel electrophoresis was done according to the
described method (30). Proteins were estimated by the folin phenol
method of Lowry et al. (31).
Electroblotting and Immunodetection—Proteins were separated on
12.5% SDS-PAGE and transblotted onto a nitrocellulose membrane in a
buffer containing 25 mM Tris, 192 mM glycine, and 20% methanol, pH
8.3, as described by Towbin et al. (32). Proteins were immunodetected
using rabbit anti-HA-binding protein antibodies (1:500) and visualized
by nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate detec-
tion system (Promega, Madison) using goat anti-rabbit alkaline phos-
phatase conjugate as secondary antibodies (1:7500).
For reprobing experiment, proteins were transblotted on ECL Hy-
bond nitrocellulose as described before. Proteins were probed first with
antirecombinant P-32 protein antibodies (1:500), second with goat anti-
rabbit horseradish peroxidase (1:10,000), and bands were visualized by
ECL kit by exactly following the manufacturer’s instructions (Amer-
sham). After band development, the blot was incubated in 62.5 mM
Tris-Cl, pH 6.7 containing 100 mM b-mercaptoethanol and 2% SDS at
50 °C for 30 min for stripping off the bound antibodies and again
blocked in 10 mM Tris-Cl, pH 8.0, containing 150 mM NaCl (TBS), 0.05%
Tween-20 (TBST), and 5% skimmed milk powder (TBSTS), reprobed
with rabbit anti-HA-binding protein antibodies (1:1000), and then proc-
essed by following the previous ECL detection method described in the
manufacturer’s kit.
Dot Blot and Transblot Assay Using Biotinylated HA—Biotinylated
HA (0.7 mg/ml) was a kind gift from Dr. K. Hoare (University of Texas
Medical Branch). Biotinylated HA assay was done according to Yang et
al. (33). The HA (human umbilical cord) and calf thymus DNA were a
commercial preparation, and rat liver total RNA was purified according
to Chomczynski and Sacchi (34). Recombinant P-32 protein was dot-
blotted on ECL Hybond nitrocellulose membrane in different concen-
trations in four slots, each having the same amount. Additional protein
binding sites were blocked in TBS, TBST, and TBSTS for 2 h. The four
blocked membranes containing the same proteins in equal amounts
were incubated separately with biotinylated HA (1:4000) alone and in
the presence of a 20-fold excess of HA, DNA, or RNA. The unlabeled
excess HA, DNA, and RNA were preincubated with biotinylated HA at
37 °C for half an hour before addition. The membranes were washed
with TBST for 4 3 10 min and then jointly incubated with avidin
peroxidase (Sigma) in 1:1500 dilution in TBST containing 2% milk
powder for 1 h. After washing with TBST (4 3 10 min), the membranes
were rinsed with TBS and developed simultaneously to visualize the
bands with ECL detection method.
For biotinylated HA transblot experiment, exactly the same proce-
dure was followed except that the boiled purified recombinant P-32
protein (with or without 5% b-mercaptoethanol in the sample buffer
containing 0.0625 M Tris-Cl, pH 6.8, 2% SDS, and 10% glycerol) were
separated on 12.5% SDS-PAGE and transblotted onto ECL Hybond
nitrocellulose (32) in a buffer containing 25 mM Tris, 192 mM glycine,
and 20% methanol, pH 8.3.
RESULTS
Purification of HA-binding Protein and Its Peptide Se-
quence—34-kDa HA-binding protein was purified from rat kid-
ney tissues (21). Antibodies raised against this purified protein
in the rabbit were affinity-purified and used for screening the
human skin fibroblast l gt11 cDNA expression library. The
peptides generated by partial protease digestion of purified
protein were separated by reverse phase high pressure liquid
chromatography and subjected to amino acid microsequencing.
An amino acid sequence of 14 peptides including the N termi-
nus of the purified protein was determined (Fig. 1).
Cloning and cDNA Sequence of the HA-binding Protein—
Using anti-HA-binding protein antibodies as probe, a clone
with a cDNA insert (;0.9 kb) was obtained by screening a
human skin fibroblast l gt11 expression library. This 0.9-kb
cDNA insert was PCR-amplified, and then a 0.4-kb PCR prod-
uct was sequenced. As shown in Fig. 2A, the deduced amino
acid sequence matches with the amino acid sequence of pep-
tides obtained from partially digested purified HA-binding pro-
tein. Interestingly, a PIR data base sequence search using the
FASTP program revealed that the amino acid and cDNA se-
quence of HA-binding protein match perfectly with the se-
quence of P-32 reported earlier by Krainer et al. (24), followed
by Honore et al. (35). This protein is co-purified with human
HeLa cell pre-mRNA splicing factor SF2 (24, 25), but the func-
tional role of P-32 is not clear. The sequence homology encour-
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aged us to sequence the rest of the 0.9-kb cDNA of HA-binding
protein with the help of two specific primers made from P-32
cDNA sequence (24). Our 852-nucleotide long partial cDNA
sequence of fibroblast HA-binding protein is shown in Fig. 2A.
This includes a 591-nucleotide coding region of open reading
frame and 39-untranslated region that is 239-nucleotides long
(excluding the poly(A) tail) containing potential polyadenyl-
ation signals (AACAAA, CATAAA) with some homology to the
consensus polyadenylation signals but not an exact match.
Moreover, it is shown that deduced amino acid sequence is
identical to the amino acid sequence derived from peptides of
protease-digested purified HA-binding protein, thus confirm-
ing the authenticity of the clone.
Homology of HA-binding Protein Sequence with P-32—The
partial cDNA sequence of HA-binding protein is completely
identical to the P-32 sequence published by Krainer et al. (24)
and Honore et al. (35). The 39-untranslated region (239 nucle-
otides excluding the poly(A) signal) is in agreement with the
reported sequence of Honore et al. (35), but in Krainer’s P-32 it
further extends up to 392 nucleotides. Krainer’s group viewed
P-32 as a full mature protein of 209 amino acids with a CTG
(Leu) initiation codon. But Honore et al. (35) observed that P-32
is produced as a proprotein of 282 amino acids with a conven-
tional ATG start codon. Honore et al. further demonstrated
that the 209-amino acid protein demonstrated by Krainer’s
group is the mature functional protein that is produced by
post-translational processing of 282-amino acid-long propro-
tein. Recently, Luo et al. (36) have isolated a murine protein
YL2 with 92% sequence homology with the mature P-32, which
modulates the function of human HIV type 1 Rev. Our obser-
vations that the composite open reading frame of HA-binding
protein obtained from N terminus data and cDNA sequence
represents the mature protein of 209 amino acids is in agree-
ment with the observations of all the above groups (Fig. 2, A
and B).
Homology of P-32 or HA-binding Protein with CD44—The
amino acid sequence of P-32 or HA-binding protein was aligned
with other HA-binding protein sequences. At the N-terminal
region of mature protein (amino acids 74–161), 14 amino acids
out of 88 possible matches were found conserved without any
break with the transmembrane and cytoplasmic domain of
CD44, the well known HA receptor (Fig. 3).
P-32 Is Antigenically Similar to HA-binding Protein—In or-
der to demonstrate the functional identity of P-32 protein, P-32
cDNA was overexpressed in Escherichia coli, and recombinant
protein in the cell extract was detected by the antibodies raised
against HA-binding protein. As shown in Fig. 4B, a single band
of 34 kDa was immunodetected in induced cell extracts (lane 4),
confirming that P-32 protein and the HA-binding protein are
homologous proteins.
Purification of P-32 Recombinant Protein by Single Step HA-
Sepharose Affinity Chromatography—The recombinant P-32
was purified (Fig. 5A) using the single step HA-Sepharose
affinity column used for purification of HA-binding protein.
The mobility of the recombinant P-32 protein is the same as
that of the purified HA-binding protein on SDS-PAGE (Fig.
4A), but on SDS-PAGE the movement of recombinant P-32,
which should actually show a molecular mass of around 24
kDa, is anomalous as already observed by Krainer et al. (24).
The isoelectric point (pI) of recombinant P-32 determined by
two-dimensional gel electrophoresis (Fig. 5B) is in conformity
with the theoretical pI of 4.04.
Immunodetection of HA-binding Protein with Anti-P-32 An-
tibodies—To study the antigenic nature of P-32, the polyclonal
antibodies were raised against the purified recombinant P-32.
As shown in Fig. 6A, both the purified P-32 and the HA-binding
protein can be detected by anti-P-32 antibodies. For further
confirmation, the P-32 antibodies used in this blot were re-
moved, the blot was reprobed with anti-HA-binding protein
antibodies, and the same band could be revisualized (Fig. 6B).
Specific Affinity of P-32 toward HA—In order to determine if
P-32 protein binds specifically to HA, varying concentrations of
purified recombinant P-32 were dot-blotted on Hybond nitro-
cellulose filters and probed with biotinylated HA. As shown in
Fig. 7A (blot D), the binding of P-32 protein to biotinylated HA
increases with the concentration of P-32. The binding of P-32 to
biotinylated HA is blocked with excess (20-fold) unlabeled HA
(blot C) showing the specific affinity of P-32 protein to HA.
Moreover, the specific binding of HA to P-32 cannot be com-
peted with a 20-fold excess of RNA (blot B) and DNA (blot A),
ruling out the possibility that P-32 is an RNA or DNA binding
protein. The specific binding of HA takes place with P-32 pro-
tein in both reducing (with b-mercaptoethanol, slot 1) and
nonreducing conditions (without b-mercaptoethanol, slot 2) in
biotinylated HA transblot experiment (Fig. 7B).
DISCUSSION
We have described here the cloning of the partial cDNA clone
for 34-kDa HA-binding protein and confirmed this protein as
P-32, a protein that co-purified with pre-mRNA splicing factor
SF2 from human HeLa cells (24, 25). The conclusion is based on
the following facts: first, both proteins, namely P-32 and HA-
binding protein, are completely identical at cDNA levels; sec-
ondly, the predicted amino acid sequence from the cDNA se-
quence of P-32 protein (24) is again almost identical with
FIG. 1. Peptide sequence of rat kidney 34-kDa HA-binding pro-
tein. A, High pressure liquid chromatogram of HA- binding protein
derived peptides. Peptides D2–D17 of HA-binding protein are shown.
The CH3CN elution gradient in 0.1% trifluoroacetic acid is shown by the
straight line. B, amino acid sequence of HA- binding protein peptides
separated in panel A. Standard amino acid code is used. X represents an
undetermined amino acid. Peptide D2 constitutes the N terminus of the
HA-binding protein.
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FIG. 2. A, triple alignment of cDNA and predicted amino acid sequences of SF2P-32 as published by Honore et al. (35) and Krainer et al. (24) and
HA-binding protein in this study. The one-letter amino acid notation is used. The inverted and upright arrows mark the initiation and termination
codon, respectively. Potential polyadenylation signals in HA-binding protein cDNA sequence are boxed. The amino acid sequences derived from
purified HA-binding protein by peptide sequencing are underlined. Closed triangles indicate potentialN-glycosylation sites. The asteriskmarks the
initiation of mature protein. SF2P32 (H) and SF2P32 (K) denote the sequence of P-32 published by Honore et al. (35) and Krainer et al. (24),
respectively. B, schematic diagram of P-32 sequence published by Honore et al. (35) (a) and Krainer et al. (24) (b) and of HA-binding protein in this
study (c). The boxed region in part a represents a proprotein that is post-translationally processed by removal of 73 amino acids at the N terminus
(dotted box) to produce a mature protein of 209 amino acids (shaded box). The N terminus of mature HA-binding protein (black region) in part c
as determined by peptide sequencing of purified HA-binding protein is missing in the partial cDNA sequence. Diagram is not drawn to scale.
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partial peptide sequences of purified HA-binding protein; and
finally, the identity of P-32 protein as HA-binding protein is
confirmed by the presence of known HA-binding motif, purifi-
cation of recombinant P-32 protein using HA-Sepharose affin-
ity chromatography, the identical electrophoretic mobility, im-
munocross-reactivity of P-32 protein with anti HA-binding
protein antibodies or vice-versa, and the specific affinity of P-32
toward HA.
The functional characteristics of P-32 are not yet known.
Krainer et al. (24) reported the sequence of P-32 cDNA, which
does not contain any conventional ATG (Met) start codon but
initiates with a CTG (Leu) codon. The matching of predicted
polypeptide sequence with the N terminus of HeLa cell purified
P-32 and the absence of upstream ATG codon or consensus 39
splice sites perhaps had led them to conclude that the mature
N terminus does not arise by proteolytic cleavage of a precur-
sor. Later, Honore et al. (35) cloned and expressed the cDNA
encoding P-32, which extends beyond the 59 end of cDNA pre-
viously reported by Krainer et al., showing that ATG is the
start codon at nucleotides 79–81, which is 12 nucleotides up-
stream of the 59 end of the sequence published by Krainer et al.
However, the N terminus sequence of P-32 protein synthesized
by cells infected with the Vaccinia virus construct of full-length
cDNA including the conventional ATG start codon gave the N
terminus amino acid sequence of P-32 as reported by Krainer et
al., clearly defining the synthesis of P-32 as a proprotein of 282
amino acids, which is post-translationally processed by re-
moval of the initial 73 amino acids to a mature protein of 209
amino acids. From our study, it is clear that the composite
amino acid sequence of HA-binding protein containing 209
residues is completely identical to that of mature P-32 protein
reported by both groups (24, 35).
Celis et al. (37, 38) reported that the synthesis of P-32 protein
is approximately 2-fold up-regulated in SV40-transformed hu-
man keratinocytes and MRC-5 fibroblasts, as compared with
their normal counterparts, implying some transformation-de-
pendent role of this protein. Our previous report has also
shown a higher expression of HA-binding protein in AK-5, a
histiocytic tumor cell line (22). Recently, P-32 has been found to
have 92% identity with a murine protein YL2 that modulates
the effects of human immunodeficiency virus type 1 Rev (36).
The open reading frame of the mature HA-binding protein
predicted the protein as a highly acidic one with 28 glutamic
acid (13.3%) and 20 aspartic acid (9.5%) residues having a
molecular mass of 24 kDa. However, both the recombinant P-32
and HA-binding protein migrate with the same electrophoretic
mobility of 34 kDa (Fig. 4A). This ambiguity may be explained
due to its highly acidic nature, as an overestimation of molec-
ular masses of highly acidic/charged proteins in SDS-PAGE is
known (39, 40). The predicted pI from the amino acid sequence
is 4.04 (24), which has been also verified experimentally
(Fig. 5B).
The mature HA-binding protein showed several interesting
features. The deduced amino acid sequence of the protein dem-
onstrated the presence of a motif, minimally required for bind-
ing to HA, referred to as BX7B, where B is either R or K and X7
is a stretch of seven basic residues in between (10). This protein
also has one such site 119KLVRKVAGEK128, which contains
one extra glutamic acid residue. Peptide mimicry experiments
(10) suggest that internal residues can vary by one amino acid
without having a detrimental effect on the ability of the protein
to bind HA. The presence of glutamic acid is also reported
in the HA-binding motif of TSG-6, a known HA-binding
protein (41).
Experimentally, the specific affinity of recombinant P-32 to
HA was shown by its binding to biotinylated HA in a concen-
tration dependent manner which can be competed only with
excess unlabeled HA but not by RNA or DNA, ruling out its
nonspecific anionic interactions. It may be mentioned here that
though P-32 is co-purified with pre-mRNA splicing factor,
Krainer et al. have already demonstrated that P-32 does not
bind to RNA (24). Furthermore, general RNA-binding motifs
RNP1 and RNP2 are also absent in P-32 although present in
the associated protein SF2. The observation that P-32 binds to
HA in both reducing and nonreducing conditions suggests the
lack of conserved cysteine residues in this protein in contrast to
CD44 and cartilage link protein (42–44). Rather P-32 behaves
like RHAMM, which also lacks conserved cysteine residues and
binds HA equally well under reducing conditions (45).
Search analysis further reveals the presence of a potential
tyrosine sulfation site (185DCHY*PEDEV193) and three N-gly-
cosylation sites (109WELELN*GTEA118, 131VTFNIN*NSIP-
PTFD144, and 218EWKDTN*YTLNT228) in the predicted amino
acid sequence. Incorporation of radiolabeled sulfate in CD44, a
well known HA receptor, is already reported (46, 47). Moreover,
this protein has a proline-directed 160PELTSTP166 sequence,
FIG. 3. Alignment of amino acid sequence of SF2P-32 or HA-
binding protein with that of CD44. The N-terminal region (amino
acids 74–161) of mature P-32 or HA-binding protein matched with the
transmembrane and cytosolic domain of CD44 (amino acids 273–360)
without any break. Box denotes conserved amino acid.
FIG. 4. Electrophoretic mobility and immunodetection of re-
combinant P-32 shown by 12.5% SDS-PAGE (A) of bacterial
(BL21(3E)) lysate containing uninduced pET3c plasmid (lane 1,
10 mg), IPTG-induced pET3c plasmid (lane 2, 10 mg), uninduced
expression plasmid with P-32 cDNA insert (lane 3, 10 mg), IPTG-
induced expression plasmid with P-32 cDNA insert (lane 4, 18
mg), or tissue-derived HA-binding protein (lane 5, 4 mg). Molecu-
lar mass markers are included at the right. B, Western blot analysis of
a similar gel, electroblotted on nitrocellulose and probed with rabbit
anti-HA-binding protein antibodies. Lanes 1–4 contain equal amounts
of the same proteins as in panel A. Lane 5 indicates molecular mass
markers.
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which may act as the substrate phosphorylation site of protein
kinases like extracellular signal-regulated kinase (ERK) (48)
and cdc2 family (49). It is already shown that the Ser/Thr-Pro
motif is sufficient for phosphorylation by ERK, and the pres-
ence of an N-terminal proline residue at least 1 amino acid
distant from the phosphorylation site in the motif increases the
efficiency of substrate recognition (50).
Sequence data further identifies the mature protein as a
multisite-phosphorylated protein, as it has one protein kinase
C phosphorylation site (202DIFS*IREVS210) and five casein
kinase II phosphorylation sites (74LHT*DGDKAFVD84,
200ESDIFS*IREV209, 208EVSFQS*TGESEWKD221, 246RGVD-
NT*FADELVEL259, and 256LVELST*ALEHQEYI269). Several
protein substrates of casein kinase II have already been iden-
tified as substrates of cdc2 kinase (51), supporting our search
data.
The presence of five casein kinase II phosphorylation sites in
the predicted sequence of HA-binding protein or P-32 protein
may further explain the association of P-32 to splicing factor
SF2 in HeLa cells. Casein kinase II is ubiquitously present in
cytosol and the nucleus of eukaryotic cells (52–54) and can also
behave as RNA-binding protein kinase (55). The C group
hnRNP protein, implicated in splicing is known to get phospho-
rylated in vivo by a casein kinase II activity (56, 57). Besides C
group hnRNP, other pre-mRNA binding proteins, mainly
UA2F, theMr 52,000 protein of trimeric U4/U6/U5, and SF2, are
FIG. 5. Purification profile and two-dimensional gel electrophoresis analysis of recombinant P-32. A, SDS-PAGE of IPTG-induced
bacterial extract containing recombinant P-32 protein (lane 2, 10 mg) and HA-Sepharose affinity-purified recombinant P-32 (lane 3, 5 mg). Low
molecular mass markers were loaded in lane 1. B, two-dimensional gel electrophoresis analysis of purified recombinant P-32. HA-Sepharose
column eluate (3 mg of protein) was subjected to isoelectric focusing over a pH range of 3.0–10.0. The focused proteins were separated by 10%
SDS-PAGE and stained with Coomassie Blue. An arrowhead denotes the P-32 recombinant protein band. Size markers are included on the left.
FIG. 6. Immunocross-reactivity between P-32 and HA-binding
protein. A, purified HA-binding protein (lane 1, 5 mg) and control
purified recombinant P-32 protein (lane 2, 5 mg) were transblotted on
nitrocellulose and first detected with the anti-P-32 antibodies. B, after
stripping off the anti-P-32 antibodies, the same blot containing HA-
binding protein (lane 1) as control was reprobed with anti-HA-binding
protein antibodies following the protocol described in the ECL kit.
FIG. 7. A, specific affinity of recombinant P-32 toward HA. Purified
HA-binding protein as control (slot 1, 10 mg) and recombinant P-32 (slot
2, 8 mg; slot 3, 6 mg; slot 4, 4 mg; slot 5, 2 mg) dot-blotted on nitrocellulose
was stained with biotinylated HA (1:4000 dilution) that had been pre-
viously blocked with milk protein for 2 h (blot D). The other three
replicate blots containing the same amount of the proteins are stained
in parallel with the same dilution of biotinylated HA in presence of
20-fold excess of unlabeled HA (blot C), liver total RNA (blot B), and calf
thymus DNA (blot A). The amount of biotinylated HA bound to the
proteins has been detected using avidin peroxidase (1:1500 dilution)
and the ECL detection system. Only unlabeled HA blocked binding of
HA-binding protein and P-32 to biotinylated HA. Succinic dehydrogen-
ase has also been used as negative control in the blot, which did not
stain with biotinylated HA (data not shown). B, biotinylated HA trans-
blot assay: Recombinant purified P-32 (5 mg in each lane) was subjected
to SDS-PAGE under reducing (1b-mercaptoethanol, lane 1) and non-
reducing conditions (2b-mercaptoethanol, lane 2), electroblotted on
nitrocellulose, and probed with biotinylated HA as described under
“Experimental Procedures.”
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phosphoproteins (58). Mayrand et al. (58) proposed that a cas-
cade of critical phosphorylation and dephosphorylation directs
their sequential binding and release for participation in the
precatalytic state of splicing reaction. In the context of complex
association of SF2 and P-32 or HA-binding protein and the
presence of multiple casein kinase II phosphorylation sites in
P-32, we assume that phosphorylation in this protein may be
regulating the splicing ability of SF2. Krainer et al. (24) did not
rule out the possibility of a role of P-32 in splicing and rather
have shown the in vitro interaction between P-32 and splicing
factor SF2.2 This observation has recently been supported by
the Peterlin group (36) confirming the interaction of YL2 or
P-32 with the basic domain of HIV type I Rev, which is impor-
tant not only for its binding to Rev response element but also
for its effect on RNA splicing in vitro. In light of the new
identity of P-32 as an HA-binding protein, further investiga-
tions can be made to explain its association with splicing factor
SF2 as well as its role in modulation of the function of human
immunodeficiency virus type 1 Rev.
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